Marc Mercken

Medicine · Health Sciences

49h-index14.8kcitations140works12.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(100), Computational Drug Discovery Methods(25), Cholinesterase and Neurodegenerative Diseases(23), Neuroscience and Neuropharmacology Research(14), Cellular transport and secretion(14)

Publications139 total

Targeting Endogenous Tau in Seeded Tauopathy Models Inhibits Tau Spread
Journal of Neuroscience·2024· 2 citedOpen Access
Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease
The Journal of Prevention of Alzheimer s Disease·2024· 22 citedOpen Access
Anti-tau intrabodies: From anti-tau immunoglobulins to the development of functional scFv intrabodies
Molecular Therapy — Methods & Clinical Development·2023· 8 citedOpen Access
Development and Characterization of Mouse-Specific Anti-Tau Monoclonal Antibodies: Relevance for Analysis of Murine Tau in Cerebrospinal Fluid
Journal of Alzheimer s Disease·2023· 1 cited
CSF p-tau increase in response to Aβ-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles
Acta Neuropathologica·2021· 35 citedOpen Access
Development of immunoprecipitation – two-dimensional liquid chromatography – mass spectrometry methodology as biomarker read-out to quantify phosphorylated tau in cerebrospinal fluid from Alzheimer disease patients
Journal of Chromatography A·2021· 22 citedOpen Access
Passive immunotherapy with a novel antibody against 3pE-modified Aβ demonstrates potential for enhanced efficacy and favorable safety in combination with BACE inhibitor treatment in plaque-depositing mice
Neurobiology of Disease·2021· 15 citedOpen Access
Alzheimer’s-causing mutations shift Aβ length by destabilizing γ-secretase-Aβn interactions
Cell·2021· 14 citedOpen Access
Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring·2021· 69 citedOpen Access
Comparison of size distribution and (Pro249-Ser258) epitope exposure in in vitro and in vivo derived Tau fibrils
BMC Molecular and Cell Biology·2020· 6 citedOpen Access
Discovery and Functional Characterization of hPT3, a Humanized Anti-Phospho Tau Selective Monoclonal Antibody
Journal of Alzheimer s Disease·2020· 22 cited
Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid
Journal of Alzheimer s Disease·2020· 21 citedOpen Access
Decreased Deposition of Beta-Amyloid 1-38 and Increased Deposition of Beta-Amyloid 1-42 in Brain Tissue of Presenilin-1 E280A Familial Alzheimer’s Disease Patients
Frontiers in Aging Neuroscience·2020· 22 citedOpen Access
Decreased deposition of Beta-Amyloid 1-38 and increased deposition of Beta-Amyloid 1-42 in brain tissue of Presenilin-1 E280A Familial Alzheimer’s disease patients
Repositorio Digital - Academia Colombiana de Ciencias Exactas, Fisicas y Naturales·2020Open Access
Central sensitization of nociceptive pathways demonstrated by robot-controlled pinprick-evoked brain potentials
Clinical Neurophysiology·2020· 21 citedOpen Access
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
Nature Communications·2020· 437 citedOpen Access
P1‐052: A SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF THE ANTI‐PHOSPHO‐TAU ANTIBODY JNJ‐63733657 IN HEALTHY SUBJECTS
Alzheimer s & Dementia·2019· 29 citedOpen Access
Extracellular interface between APP and Nicastrin regulates Aβ length and response to γ‐secretase modulators
The EMBO Journal·2019· 52 citedOpen Access
Design and synthesis of a novel series of cyanoindole derivatives as potent γ-secretase modulators
Bioorganic & Medicinal Chemistry Letters·2019· 7 citedOpen Access
Anti-Tau Monoclonal Antibodies Derived from Soluble and Filamentous Tau Show Diverse Functional Properties in vitro and in vivo
Journal of Alzheimer s Disease·2018· 40 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Ralph A. Nixon(8), Paul M. Mathews(6), Bianca Van Broeck(6), Bart De Strooper(5), Stephen D. Schmidt(5), Harrie J. M. Gijsen(5), Ying Jiang(4), Marc Vandermeeren(4), Kurt Spittaels(4), Chris Van den Haute(4), Jo Van Dorpe(4), Koen Bruynseels(4), Ruth J. F. Loos(4), Didier Berthelot(4), Eric Karran(3), Karen Duff(3), Anne M. Cataldo(3), Jan Six(3), A. Van de Voorde(3), Niklas Mattsson(3)